Piper Sandler analyst Joseph Catanzaro downgraded Turnstone Biologics (TSBX) to Neutral from Overweight with a price target of 40c, down from $3.75, after the company announced it is discontinuing all of its clinical studies evaluating TIDAL-01 and is exploring strategic alternatives. Piper removed all value for TIDAL-01 and downgraded the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX: